Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML2521

Sigma-Aldrich

BRD6929

≥98% (HPLC)

Sinonimo/i:

4-(Acetylamino)-N-[2-amino-5-(2-thienyl)phenyl]benzamide, BRD6929, Compound 60, TPB

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C19H17N3O2S
Numero CAS:
Peso molecolare:
351.42
Numero MDL:
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

−20°C

Stringa SMILE

CC(NC1=CC=C(C(NC2=C(N)C=CC(C3=CC=CS3)=C2)=O)C=C1)=O

Azioni biochim/fisiol

TPB is a potent and selective inhibitor of HDAC1 and HDAC2. TPB potentiates gnidimacrin activation of latent HIV-1 in cells.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Li Huang et al.
ACS medicinal chemistry letters, 9(3), 268-273 (2018-03-16)
We have previously reported gnidimacrin (GM), a protein kinase C (PKC) agonist, significantly reduces the frequency of HIV-1 latently infected cells in peripheral blood mononuclear cells (PBMCs) from patients undergoing successful antiretroviral therapy at low picomolar concentrations ex vivo, which
Stefan Kubicek et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(14), 5364-5369 (2012-03-22)
Under the instruction of cell-fate-determining, DNA-binding transcription factors, chromatin-modifying enzymes mediate and maintain cell states throughout development in multicellular organisms. Currently, small molecules modulating the activity of several classes of chromatin-modifying enzymes are available, including clinically approved histone deacetylase (HDAC)
F F Wagner et al.
Chemical science, 6(1), 804-815 (2015-02-03)
Aiming towards the development of novel nootropic therapeutics to address the cognitive impairment common to a range of brain disorders, we set out to develop highly selective small molecule inhibitors of HDAC2, a chromatin modifying histone deacetylase implicated in memory
Joey L Methot et al.
Bioorganic & medicinal chemistry letters, 18(3), 973-978 (2008-01-10)
We report herein the initial exploration of novel selective HDAC1/HDAC2 inhibitors (SHI-1:2). Optimized SHI-1:2 structures exhibit enhanced intrinsic activity against HDAC1 and HDAC2, and are greater than 100-fold selective versus other HDACs, including HDAC3. Based on the SAR of these
Andrew J Wilson et al.
Cancer biology & therapy, 12(6), 484-493 (2011-07-09)
High grade epithelial ovarian cancers are relatively sensitive to DNA damaging platinum-based chemotherapy, suggesting that the dependencies of ovarian tumors on DNA damage response pathways can be harnessed for therapeutic purposes. Our goal was to determine if the DNA damage

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.